Acworth Pharmaceuticals is pioneering the discovery and development of first-in-class regulatory therapeutics that kill cancer by restoring normal cellular function. Acworth is using its platform to discover and develop direct-acting regulators that restore normal recycling function to signaling pathways disrupted in cancer.  In many cancers, the ability to return dysregulated signaling molecules to a normal state in the cell is compromised by the loss of key factors that initiate the recycling process. Acworth is succeeding where other approaches fail.